Abstract 3607
Background
We aimed to establish a prognostic model based on magnetic resonance imaging using deep learning to predict disease-free survival in patients with non-metastatic nasopharyngeal carcinoma.
Methods
In this retrospective, cohort study, we included 1636 patients who were diagnosed with non-metastatic nasopharyngeal carcinoma and underwent radical treatment at the Sun Yat-sen University Cancer Center. Patients from October 2010 to March 2015 were randomly divided into training cohort (n = 878) and validation cohort (n = 376); 382 patients from April 2015 to September 2015 were separated as test cohort. 3D DenseNet models learned deep representations of pre-treatment MRI and risk scores were extracted to predict PFS in the training cohort. We evaluated the accuracy of the prognostic model in validation and test cohorts. The primary endpoint was DFS, and the secondary endpoint was distant metastasis-free survival (DMFS).
Results
A series of risk scores for each patient were extracted from 3D DenseNet models, and an optimal cut-off value of risk scores was generated to classify patients into low-risk and high-risk group in the training cohort. Patients with low-risk scores had better DFS (hazard ratio [HR] 0.62, 95% CI 0.55 -0.70; p < 0.0001) and DMFS (HR 0.62, 95% CI 0.48 -0.81; p < 0.0003) than patients with low-risk scores. And we validated the prognostic accuracy of risk scores in the validation and test cohorts. In addition, patients who received concurrent chemotherapy had a poorer DFS (hazard ratio [HR] 7.79, 95% CI 1.08 -56.00; p < 0.041) compared with those who did not receive concurrent chemotherapy in low-risk group, meanwhile, patients with or without concurrent chemotherapy had similar outcomes in the high-risk group (HR 2.39, 95% CI 0.59 -9.62; p = 0.22). We also developed a nomogram based on risk scores and several clinical factors that predicted an individual’s risk of DFS.
Conclusions
MRI-based 3D DenseNet models are effective tools to learn deep representations and extract risk scores of DFS. Risk scores can be reliable prognostic factors to select which patients benefit from concurrent chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract